Value-Based Pricing Is in Place, but Prices for a Single Drug Vary

Value-based pricing has become an important topic of discussion in healthcare in the United States. Although value-based pricing is intended to regulate prices of drugs based on their actual value, prices for a single drug can still vary significantly.

Authors Anna Kaltenboeck, MA, and Peter B. Bach, MD, both of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, suggested that value-based pricing has refined itself and now can initiate any change to traditional payment models for drugs, which does not necessarily consider the final price of the product.

“The current system, in which prices reflect 'what the market will bear,' has been plagued by price hikes on legacy drugs and wide dissociations between prices of drugs and their benefits,” the authors of an article, published by JAMA, stated. “The cost of a year of life gained with cancer treatment has been increasing annually by $8500 as a result of accelerating prices for new oncology drugs.”

There is an indication-specific pricing approach that suggests the same drug can have higher and lower prices when the benefits in its indications differ substantially. This specific approach has previously been implemented by both Express Scripts and CVS Caremark for cancer drugs, while Novartis has announced that its drug tisagenlecleucel (Kymriah) will have indication-specific prices.


Recent Posts

See All

How would Medicare for All really work?

By Albert DiPiero MD MPH As the hype for Medicare For All ramps up ahead of the 2020 presidential election, it seems important and imperative to at least start discussing how this would work. There is

A hidden referral system that guides doctors

Learn about the battle between “Keepage” versus “Leakage.” Physicians working for hospital-based systems are being increasingly monitored and pressured to Keep referrals within their system, regardle